膀胱癌是泌尿外科常见的恶性肿瘤之一,浅表性膀胱癌占70％～80％,可经手术切除取得较好的近期疗效,但复发率高,达50％～70％。膀胱灌注治疗作为一种首选的局部治疗方法,BCG为公认的最有代表性的药物之一,但复发率为18.9％,而且有较多的局部和全身反应。因此,研究利用新的药物成为学者们关注的焦点。本文仅对吡柔比星在膀胱癌患者的临床应用现状做一综述。 Bladder cancer is one of the most common malignant tumors in urology. Superficial bladder cancer accounts for 70% ~ 80%, which can be surgically removed to achieve better short-term curative effect. However, the recurrence rate is as high as 50% -70%. Bladder infusion therapy As one of the preferred topical treatments, BCG is one of the most recognized and representative drugs with a recurrence rate of 18.9% and more local and systemic reactions. Therefore, the study of the use of new drugs has become the focus of scholars. This article only pirarubicin in bladder cancer in patients with clinical application status are reviewed.